Ultrasound for prostate imaging and biopsy

Current Opinion in Urology

Volumn 11, Issue 5, 2001, Pages 471-477

  Ismail, Mohammed ^a   Gomella, Leonard G ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ECHOGRAPHY; HUMAN; NEEDLE BIOPSY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; SAMPLING; TRANSRECTAL ULTRASONOGRAPHY;

BIOPSY, NEEDLE; CONTRAST MEDIA; HUMANS; IMAGE ENHANCEMENT; IMMUNOHISTOCHEMISTRY; MALE; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 0034874968     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200109000-00004     Document Type: Review

References (73)

1. Random systematic versus directed ultrasound guided transrectal care biopsies of the prostate
2. Prostate-specific antigen: Current status
3. Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer
4. Clinical significance of repeat sextant biopsies in prostate cancer patients
5. Making the mast out of six systematic sextant biopsies
6. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate
7. Computer-assisted comparative analysis of four-sector and six-sector biopsies of the prostate
8. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: Results of a prospective clinical trial
9. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer
10. Twelve systematic prostate biopsies are superior to sextant biopsies for diagnosing carcinoma: A prospective randomized study
11. Endorectal color Doppler sonography and endorectal MR imaging features of nonpalpable prostate cancer: Correlation with radical prostatectomy findings
12. Peripheral hypoechoic lesions of the prostate: Evaluation with color and power Doppler ultrasound
13. The usefulness of power Doppler ultrasonography for diagnosing prostate cancer: Histological correlation of each biopsy site
14. The role of colour Doppler ultrasonography in detecting prostate cancer
15. Transrectal power Doppler imaging in the detection of prostate cancer
16. Initial experience with contrast-enhanced sonography of the prostate
17. Three-dimensional contrast-enhanced power Doppler ultrasonography and conventional examination methods: The value of diagnostic predictors of prostate cancer
18. Three-dimensional ultrasound analyses of the prostate
19. New developments in ultrasonography for the detection of prostate cancer
20. Is sextant prostate biopsy the standard of care in the PSA era?
21. European randomized study of screening for prostate cancer - The Rotterdam pilot studies
22. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: Relation to biopsy strategy
23. Value of systematic transition zone biopsies in the early detection of prostate cancer
24. Indications for transition zone biopsy in the detection of prostatic carcinoma
25. Pain and morbidity of transrectal ultrasound guided prostate biopsy: A prospective randomized trial of 6 versus 12 cores
26. Impact of transrectal ultrasound guided prostate biopsy on quality of life: A prospective randomized trial comparing 6 versus 12 cores
27. Detection of prostate cancer: A comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy
28. Patients with abnormal ultrasound of the prostate but normal digital rectal examination should be classified as having clinical stage T2 tumors
29. Predictive value of contralateral biopsies in unilaterally palpable prostate cancer
30. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy
31. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update
32. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy
33. Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer
34. Use of systematic biopsy results to predict pathologic stage in patients with clinically localized prostate cancer: A preliminary report
35. Preoperative predictors for organ-confined disease in Japanese patients with stage T1c prostate cancer
36. Is the percentage of cancer in biopsy cores predictive of extracapsular disease in T1-T2 prostate carcinoma?
37. A single positive prostate biopsy in six does not predict a low-volume prostate tumour
38. Ability of sextant biopsies to predict radical prostatectomy stage
39. Sextant prostate biopsies: A histopathologic correlation with radical prostatectomy specimens
40. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis
41. Large, organ confined, impalpable transition zone prostate cancer: Association with metastatic levels of prostate specific antigen
42. Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies
43. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer
44. Impalpable invisible stage T1c prostate cancer: Characteristics and clinical relevance in 100 radical prostatectomy specimens - A different view
45. Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade
46. Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal examination, prostate specific antigen and the results of 6 systematic biopsies
47. Advances in angiogenesis research: Relevance to urological oncology
48. Microvessel density in prostate cancer: Prognostic and therapeutic utility
49. Tumor angiogenesis: Review of current applications in tumor prognostication
50. Comparison of microscopic vascularity in benign and malignant prostate tissue
51. Quantitative morphometric analysis of the microcirculation in prostate carcinoma
52. Color Doppler flow imaging
53. Influence of various instrument settings on the flow information derived from the power mode
54. Ultrasound contrast agents: Basic principles
55. On the feasibility of real-time, in vivo harmonic imaging with proteinaceous microspheres
56. Second harmonic ultrasonic blood perfusion measurement
57. Contrast-enhanced three-dimensional power Doppler angiography of the human prostate: Correlation with biopsy outcome
58. Prostate: Techniques, results, and potential applications of color Doppler US scanning
59. Prostate cancer: Diagnosis with color Doppler sonography with histologic correlation of each biopsy site
60. The diagnostic value of colour Doppler flow in the peripheral zone of the prostate, with histological correlation
61. Color Doppler imaging in predicting the biologic behavior of prostate cancer: Correlation with disease-free survival
62. Three-dimensional power Doppler detection of prostatic cancer
63. Kinetic study of tumor blood flow in prostatic cancer using power Doppler imaging
64. Preliminary results of power Doppler imaging in benign prostatic hyperplasia
65. Diffuse prostatic lesions: Role of color Doppler and power Doppler ultrasonography
66. Power Doppler ultrasonography and hypoechoic nodules of the peripheral prostate: Prospectives and limitations
67. The role of power Doppler ultrasonography in the diagnosis of prostate cancer: A preliminary study
68. Using gray-scale and color and power Doppler sonography to detect prostatic cancer
69. Ultrasound contrast agents: A review
70. Transrectal ultrasound microbubble contrast angiography of the prostate
71. Statistical framework for ultrasonic spectral parameter imaging
72. In vitro investigation of lymph node metastasis of colorectal cancer using ultrasonic spectral parameters
73. Artificial neural network analysis (ANNA) of prostatic transrectal ultrasound